» Articles » PMID: 31547767

Relationship Between Troponin on Presentation and In-Hospital Mortality in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Overview
Date 2019 Sep 25
PMID 31547767
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background Troponin release in ST-segment-elevation myocardial infarction (STEMI) has predictable kinetics with early levels reflective of ischemia duration. Little research has examined the value of admission troponin levels in STEMI patients undergoing primary percutaneous coronary intervention. We investigated the relationship between troponin on presentation and mortality in a large, real-world cohort of STEMI patients undergoing primary percutaneous coronary intervention. Methods and Results We used multivariable adaptive regression modeling to examine the association between admission troponin levels and in-hospital mortality for patients who underwent primary percutaneous coronary intervention for STEMI. We adjusted for known clinical risk factors using a validated mortality risk model derived from the NCDR (National Cardiovascular Data Registry) CathPCI database, and this same model was used to calculate patients' predicted mortality based on clinical and demographic factors. Patients were then stratified by troponin groups to compare predicted versus observed mortality. Of the 14 061 patients included in the cohort, 47.2% had initial troponin levels that were undetectable or within the reference range. Admission troponin was an independent predictor of in-hospital mortality, and any value above the reference range was associated with increased mortality (1.8% versus 5.1%, [standardized difference, 18.2%]). Patients with the highest predicted risk for mortality (13% predicted) in the highest admission troponin grouping experienced an observed mortality of 19.5%. Patients in low troponin groupings consistently demonstrated lower than predicted mortality based on their clinical and demographic risk profile. Conclusions Nearly half of patients undergoing primary percutaneous coronary intervention had normal troponin on presentation and had a relatively good outcome. Mortality increases with elevated admission troponin levels, regardless of baseline clinical risk. The substantial number of patients who present with markedly elevated troponin and their relatively worse outcomes highlights the need for continued improvement in prehospital STEMI detection and care.

Citing Articles

Time to Treatment Delay and Clinical Indicators in Patients with ST-Segment Elevation Myocardial Infarction: A Descriptive Cross-sectional Study.

Motadayen M, Feizollahzadeh H, Taban M, Dehganneghad J J Caring Sci. 2025; 13(4):286-293.

PMID: 39974833 PMC: 11833435. DOI: 10.34172/jcs.33506.


Beyond STEMI-NSTEMI Paradigm: Dante Pazzanese's Proposal for Occlusion Myocardial Infarction Diagnosis.

de Alencar J, Feres F, De Marchi M, Franchini K, Scheffer M, Felicioni S Arq Bras Cardiol. 2024; 121(5):e20230733.

PMID: 39016396 PMC: 11216332. DOI: 10.36660/abc.20230733.


Clinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing.

Maayah M, Grubman S, Allen S, Ye Z, Park D, Vemmou E Diagnostics (Basel). 2024; 14(5).

PMID: 38472975 PMC: 10930800. DOI: 10.3390/diagnostics14050503.


Cardiac Troponin I but Not N-Terminal Pro-B-Type Natriuretic Peptide Predicts Outcomes in Cardiogenic Shock.

Schupp T, Rusnak J, Forner J, Weidner K, Ruka M, Egner-Walter S J Pers Med. 2023; 13(9).

PMID: 37763116 PMC: 10532680. DOI: 10.3390/jpm13091348.


In-Hospital Mortality Outcomes of ST-Segment Elevation Myocardial Infarction: A Cross-Sectional Study from a Tertiary Academic Hospital in Johannesburg, South Africa.

Ndaba L, Mutyaba A, Mpanya D, Tsabedze N J Cardiovasc Dev Dis. 2023; 10(8).

PMID: 37623361 PMC: 10455389. DOI: 10.3390/jcdd10080348.


References
1.
Stewart J, French J, Theroux P, Ramanathan K, Solymoss B, Johnson R . Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol. 1998; 31(7):1499-505. DOI: 10.1016/s0735-1097(98)00139-9. View

2.
Cannon C, Gibson C, LAMBREW C, Shoultz D, Levy D, French W . Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000; 283(22):2941-7. DOI: 10.1001/jama.283.22.2941. View

3.
Chia S, Senatore F, Raffel O, Lee H, Wackers F, Jang I . Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2009; 1(4):415-23. DOI: 10.1016/j.jcin.2008.04.010. View

4.
Peterson E, Dai D, DeLong E, Brennan J, Singh M, Rao S . Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol. 2010; 55(18):1923-32. PMC: 3925678. DOI: 10.1016/j.jacc.2010.02.005. View

5.
Kline-Rogers E, Share D, Bondie D, Rogers B, Karavite D, Kanten S . Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol. 2002; 15(5):387-92. DOI: 10.1111/j.1540-8183.2002.tb01072.x. View